360 related articles for article (PubMed ID: 27912846)
1. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Gabizon AA; Patil Y; La-Beck NM
Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):707-20. PubMed ID: 21434836
[TBL] [Abstract][Full Text] [Related]
8. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Soloman R; Gabizon AA
Clin Lymphoma Myeloma; 2008 Feb; 8(1):21-32. PubMed ID: 18501085
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
11. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
[TBL] [Abstract][Full Text] [Related]
14. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
[TBL] [Abstract][Full Text] [Related]
15. [Doxil--pegylated liposomal doxorubicin].
Sekiya N; Imamura A
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1439-43. PubMed ID: 18701868
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
17. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.
Muggia FM
Drugs; 1997; 54 Suppl 4():22-9. PubMed ID: 9361958
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
20. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
